Clinical Trials Logo

Clinical Trial Summary

The purpose of this study was to assess the long-term safety and efficacy of ABBV-8E12 (tilavonemab) in participants with progressive supranuclear palsy (PSP).


Clinical Trial Description

This study (M15-563) was a Phase 2, randomized, double-blind, multiple-dose, multicenter, long-term extension of NCT 02985879 (Study M15-562) in participants with progressive supranuclear palsy (PSP). Those who completed the 52-week Treatment Period in Study M15-562 and met all entry criteria were eligible for enrollment into this study. This study planned for a Treatment Period of up to 5 years and a post-treatment follow-up visit approximately 20 weeks after the last dose of study drug (including participants who prematurely discontinued treatment). All participants received ABBV-8E12 as follows: those who received placebo in Study M15-562 were randomized, in a 1:1 ratio, to either 2000 or 4000 mg; those who received ABBV-8E12 at a dose of either 2000 or 4000 mg in Study M15-562 continued on the same dose in this study. This study was prematurely discontinued because the program for progressive supranuclear palsy was discontinued due to lack of efficacy. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03391765
Study type Interventional
Source AbbVie
Contact
Status Terminated
Phase Phase 2
Start date January 24, 2018
Completion date December 13, 2019

See also
  Status Clinical Trial Phase
Completed NCT02365922 - Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL)
Recruiting NCT03030586 - ADDIA Proof-of-Performance Clinical Study
Recruiting NCT02778607 - PROgressive Supranuclear Palsy CorTico-Basal Syndrome Multiple System Atrophy Longitudinal Study UK
Completed NCT02531360 - Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies Phase 0
Completed NCT02133846 - Safety Study of TPI-287 to Treat CBS and PSP Phase 1
Recruiting NCT04363684 - ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
Completed NCT04193527 - A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients Phase 3
Completed NCT02839642 - Efficacy of RIVAstigmine on Motor, Cognitive and Behavioural Impairment in Progressive Supranuclear Palsy Phase 3
Active, not recruiting NCT02966145 - 4-Repeat Tauopathy Neuroimaging Initiative - Cycle 2
Completed NCT02103894 - Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects Phase 1
Active, not recruiting NCT04539041 - Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy Phase 1
Completed NCT01888185 - Identifying Biomarkers of Parkinson's Disease Using Magnetic Resonance Imaging (MRI)
Completed NCT03545126 - Human CNS Tau Kinetics in Tauopathies
Completed NCT03413319 - Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104 Phase 1